Company Overview
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Why Investors Should Care
Revenue has grown at a 19.2% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $3.09M (-11.6% YoY); net profit $-7.36M.
- Trailing 12 Months Year-on-year growth — revenue -0.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 19.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 19.20% |
| 1 Year: | -0.60% |
Stock Price Performance
| 1 Year: | -36.57% |
| 6 Months: | -34.99% |
| 3 Months: | -25.70% |
| 1 Month: | -47.99% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)25.40 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 19.2% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 64.6% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DYAI Dyadic International, Inc. PHARMA | 0.52 | -2.48 | $20.83M | 0.00% | -114.93% | - | 19.20% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 184.33K | 161.29K | 262.96K | 402.53K | 390.87K | 454.51K | 315.37K | 524.27K | 416.36K | 460.52M | 937.09K | 692.93K | 648.43K | 658.55K | 879.60K | 978.05K | 837.16K | 397.06K | 334.62K | 385.90K | 1.96M | 393.57K | 966.63K | 1.16M | 1.11M |
| Operating Income | -2.23M | -1.82M | -1.78M | -2.44M | -2.96M | -1.94M | -2.38M | -2.80M | -2.58M | -3.32B | -3.87M | -3.32M | -2.74M | -3.32M | -1.86M | -2.05M | -2.29M | -1.72M | -2.13M | -2.04M | -202.61K | -2.00M | -1.73M | -1.93M | -1.90M |
| Net Income | -2.04M | -1.60M | -1.54M | -2.18M | -2.70M | -1.70M | -2.21M | -2.65M | -2.50M | -3.29M | -3.85M | -1.72M | -2.49M | -3.29M | -1.81M | -956.44K | -2.15M | -1.61M | -2.01M | -2.05M | -203.46K | -2.03M | -1.79M | -1.98M | -1.95M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.07 | -0.01 | -0.07 | -0.06 | -0.06 | -0.05 |
| R&D Expense | 576.88K | 601.20K | 476.63K | 692.37K | 818.24K | 841.34K | 755.45K | 1.12M | 986.05K | 1.81B | 2.21M | 1.90M | 1.34M | 1.83M | 743.59K | 810.57K | 917.55K | 716.35K | 522.72K | 515.63K | 460.24K | 494.98K | 629.38K | 571.87K | 476.07K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 758.42K | 1.30M | 1.68M | 1.60M | 2.40M | 2.93M | 2.90M | 3.50M | 3.09M |
| Operating Income | -7.13M | -7.59M | -9.28M | -10.03M | -14.73M | -10.17M | -8.23M | -5.90M | -7.19M |
| Net Income | -2.14M | -5.69M | -8.31M | -9.33M | -13.07M | -9.74M | -6.80M | -5.81M | -7.36M |
| Diluted EPS | - | - | - | - | - | - | - | -0.20 | -0.23 |
| R&D Expense | 1.77M | 2.10M | 3.09M | 3.87M | 8.39M | 4.50M | 3.30M | 2.04M | 2.15M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 50.74M | 43.30M | 37.45M | 30.07M | 21.30M | 13.71M | 8.22M | 9.93M | 9.95M |
| Total Equity | 57.69M | 49.98M | 42.45M | 35.86M | 28.45M | 18.39M | 11.09M | 5.88M | 2.47M | 1.23M |
| Cash & Equivalents | - | 5.79M | 2.39M | 4.82M | 20.64M | 15.75M | 5.79M | 6.52M | 6.51M | 4.62M |
| Total Liabilities | - | - | - | - | 1.63M | 2.91M | 2.63M | 2.34M | 7.46M | 8.71M |
| Current Liabilities | - | 768.89K | 849.64K | 1.59M | 1.63M | 2.56M | 2.45M | 2.25M | 2.45M | 3.69M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.69M | -4.41M | -5.78M | -6.57M | -11.28M | -8.08M | -6.73M | -3.97M | -5.70M |
| Investing Cash Flow | -812.08K | 3.33M | 7.71M | 22.12M | 5.22M | -2.37M | 7.45M | -1.88M | 82.08K |
| Financing Cash Flow | -6.22M | -2.30M | 550.19K | 255.47K | 1.23M | 543.59K | 0 | 5.85M | 4.96M |
| Share Buybacks | 6.22M | 2.30M | 0 | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -939.7% | -586.1% | -552.2% | -625.9% | -612.7% | -346.9% | -283.9% | -168.8% | -232.8% |
| Net Margin % | -281.6% | -439.4% | -494.2% | -582.1% | -543.7% | -332.2% | -234.4% | -166.2% | -238.3% |
| ROE % | -4.3% | -13.4% | -23.2% | -32.8% | -71.1% | -87.8% | -115.6% | -235.2% | -597.6% |
| ROCE % | -14.3% | -17.9% | -25.9% | -35.2% | -78.6% | -90.2% | -137.9% | -78.9% | -114.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 3.47% | 928.23K | $385.22K |
| 2 | Chapin Davis, Inc. | 3.32% | 888.00K | $368.52K |
| 3 | Apis Capital Advisors, LLC | 3.01% | 804.88K | $334.03K |
| 4 | Truist Financial Corp | 1.22% | 326.20K | $135.37K |
| 5 | Geode Capital Management, LLC | 0.94% | 250.91K | $104.12K |
| 6 | Blackrock Inc. | 0.74% | 197.75K | $82.06K |
| 7 | Vanguard Fiduciary Trust Co | 0.52% | 139.48K | $57.88K |
| 8 | Marathon Capital Management | 0.41% | 110.00K | $45.65K |
| 9 | Sage Mountain Advisors, LLC | 0.40% | 106.56K | $44.22K |
| 10 | HighTower Advisors, LLC | 0.30% | 79.47K | $32.98K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DYAI
Dyadic Says Pilot Process Boosted Transferrin Productivity ~80% - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOVWZPSHN6QlN4ejUwQm1VM3hwNE8wMGlnNnZ1VE5pYmJPRjZHY2E1aERDNWxUM3pPMDI3ZnVXM21tNmdCdEVvbU5zZDZhbXdBSXU3VWhyZzFwdTJ1TmJPcUZld1o4UGpmbWhhUE9VOVIySUVPcm9vVkhVSENaYi02RldEN21NSnJkYjgyNV…
DYAI - Dyadic International Inc, DE Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE10S3hONXlXNmdiQVBsR0drbnFWTnZGOW0wT1F0SDRPTTJZbEloNWRtNDdhdmVPLW1LMXVsUnBLQXNLc2ZwRVE?oc=5" target="_blank">DYAI - Dyadic International Inc, DE Stock Price and Quote</a>  …
Analysts Expect Breakeven For Dyadic International, Inc. (NASDAQ:DYAI) Before Long - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxNa3ZMYnNEUU5JYXJ6aXUtSHRrbGRJQm16VEJDdzFsQUd4bWlZWm9SRHlaRmVNRFo3dlhkZlNHS3hIczRXdkNJQjZpSmR6bFZHZ05uOF9qYVZUOWt6VnlOdktoWUpJWXJvQkZGVHRLMXZqNWQ4aVlQNnBmWUxoc1hXSUV4bFFoUlBTM3Brem…
DYAI Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE55R2k1ZjNOUmktMU9ibHBRdnY3dVVISlc0VDdNdVJjZVd5QTN0dFJacFNZNkFYRWdFeGRsQXRQcWFQbmdES21SdURkX20xZEw5azh4RFpDYnRRbnNpYXd0WTQ3NFJkSXY0ZWlnSHhiUnNOaWkwUmNfS3Vn?oc=5" target="_blank">DYA…
Insider Sale: 10% owner at $DYAI Sells 25,281 Shares - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQbTFYZlQzNDBNOW8zaHVjdWFDSTlYcnVZRjRnaWRHSGE2M0dZZzJlM3cwbi00QlpBRFJoNk5IVjc1aTVYbEptQlA0N050WmtJQ3lTRGxMdFdTckplS1o0Z05MRGMzT3pfZi1GazdpQTc5NzVBSFZ3eVRGQmM4NWljWWlCalE4MlJRZndXcU…
Dyadic International Announces New Equity Financing Agreements - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxQTVRRRTgwS2liQUI5WTIyb0NPa25QdVF2M2l5dkd5WWE1Z1M2TDdBTFl0MWtmNjJzU3lyNjdwaXZSZnBkdFM5M0tfeV9oYnpXcm5Cc1JacTBmamZKM01NQzFKbVdrLXItWFBfcHM2OWdzRDZaT3E2eF9SWnpEOWpuSEQ1OW1EN2h5bVV6Nl…
DYAI — Frequently Asked Questions
What is the current share price of Dyadic International, Inc. (DYAI)?
As of 2026-09-19 21:16 PDT, Dyadic International, Inc. (DYAI) trades at $0.52 on NasdaqCM. Its 52-week range is $0.50 to $1.47.
What is the market capitalisation of DYAI?
Dyadic International, Inc. (DYAI) has a market capitalisation of $20.83M on NasdaqCM.
What is the P/E ratio of DYAI?
DYAI trades at a trailing price-to-earnings (P/E) ratio of -2.48. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -7.79.
Is DYAI a good stock to buy?
This page provides a data-driven analysis of Dyadic International, Inc. (DYAI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.